Ownership and insider activity for Harvard Bioscience, Inc. (HBIO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the Americas, Europe, the Middle East, Africa, Asia, and internationally.
Price
| Price | $7.97 |
| Market Cap | $36M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-09 | Eade Katherine A. | A-Award | 16,556 | |
| 2026-06-09 | Snider William | A-Award | 16,556 | |
| 2026-06-09 | DENELSKY STEPHEN J | A-Award | 16,556 | |
| 2026-06-09 | Gagnon Robert E. | A-Award | 16,556 | |
| 2026-06-09 | Benson Seth Benjamin | A-Award | 16,556 | |
| 2026-03-20 | Frost Mark T | A-Award | 30,000 | |
| 2026-03-16 | Frost Mark T | P-Purchase | 5,000 | $25K |
| 2026-03-20 | Duke John D | A-Award | 75,000 | |
| 2026-03-17 | DENELSKY STEPHEN J | P-Purchase | 10,000 | $49K |
| 2026-03-17 | Snider William | P-Purchase | 8,475 | $41K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.6M | $5.7M | $8.2M | $8.3M | $8.3M | $7.8M | $4.5M | $4.3M | $4.1M | $8.6M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $19.9M | $17.1M | $21.5M | $20.7M | $17.8M | $21.8M | $16.7M | $16.1M | $14.9M | $16.0M |
| Inventory | $20.0M | $21.4M | $25.1M | $22.1M | $22.3M | $27.6M | $26.4M | $24.7M | $23.2M | $20.8M |
| Total Current Assets | $45.5M | $47.5M | $54.7M | $53.6M | $51.7M | $61.6M | $51.1M | $49.0M | $45.1M | $48.2M |
| Property, Plant & Equipment | $4.3M | $4.1M | $5.9M | $13.2M | $11.7M | $10.3M | $9.2M | $8.8M | $11.2M | $4.8M |
| Goodwill | $38.0M | $40.0M | $57.3M | $57.4M | $58.6M | $57.7M | $56.3M | $57.1M | $56.3M | $9.6M |
| Intangible Assets | $18.7M | $17.2M | $45.8M | $38.4M | $33.2M | $27.4M | $21.0M | $16.0M | $11.1M | $7.6M |
| Total Assets | $107.8M | $109.4M | $168.1M | $164.9M | $156.3M | $162.3M | $145.4M | $137.4M | $126.6M | $80.1M |
| Accounts Payable | $6.2M | $4.4M | $7.4M | $5.3M | $6.0M | $4.9M | $6.4M | $5.6M | $4.8M | $3.7M |
| Short-term Debt | $2.4M | $2.8M | $2.0M | $6.9M | $1.7M | $3.2M | $3.8M | $5.9M | $37.0M | $1.5M |
| Total Current Liabilities | $14.6M | $14.0M | $21.5M | $25.3M | $21.1M | $25.3M | $23.2M | $26.5M | $55.0M | $22.0M |
| Long-term Debt | $11.4M | $9.0M | $58.8M | $46.9M | $46.3M | $45.1M | $43.0M | $30.7M | 0 | $35.9M |
| Total Liabilities | $35.6M | $28.5M | $85.9M | $83.2M | $79.6M | $78.9M | $73.1M | $64.3M | $63.3M | $66.3M |
| Retained Earnings | -$116.0M | -$117.0M | -$119.9M | -$124.6M | -$132.4M | -$132.7M | -$142.2M | -$145.6M | -$158.0M | -$214.7M |
| Total Equity | $72.2M | $80.9M | $82.2M | $81.7M | $76.7M | $83.4M | $72.2M | $73.1M | $63.3M | $13.7M |
| Total Debt | $13.7M | $11.7M | $60.8M | $64.5M | $57.6M | $57.0M | $54.2M | $42.8M | $44.5M | $44.3M |
| Net Debt | $8.2M | $6.0M | $52.6M | $56.1M | $49.3M | $49.1M | $49.7M | $38.5M | $40.4M | $35.7M |
| Working Capital | $30.9M | $33.5M | $33.2M | $28.3M | $30.6M | $36.3M | $27.9M | $22.5M | -$9.8M | $26.3M |
Financial Health
| Debt / Equity | 5.96 |
| Current Ratio | 1.87 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -2.04 |
Profitability
| Return on Equity | -92.01% |
| Return on Invested Capital | 1.91% |
| Return on Assets | -13.65% |
| Gross Margin | 58.16% |
| Operating Margin | 1.17% |
| Net Margin | -11.86% |
Related companies: CLGN · COSM · FEMY · NCNA · NXGL · NXL · RVP
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of HBIO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks